Zelira Therapeutics (ASX:ZLD) Total Receivables: A$0.03 Mil (As of Jun. 2025)


What is Zelira Therapeutics Total Receivables?

Zelira Therapeutics ASX:ZLD Total Receivables is A$0.03 Mil as of Jun. 2025. The stock has 7 warning signs investors should review.

Zelira Therapeutics's Total Receivables for the quarter that ended in Jun. 2025 was A$0.03 Mil.

Zelira Therapeutics Total Receivables Related Terms

Zelira Therapeutics Total Receivables Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Total Receivables Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.26 -0.00 0.20 0.03

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.68 0.20 0.20 0.03

Zelira Therapeutics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of A$0.03 Mil mean?
Zelira Therapeutics (ASX:ZLD) has a Total Receivables of A$0.03 Mil as of Jun. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' Total Receivables too high?
Zelira Therapeutics' current Total Receivables is A$0.03 Mil.
How does Zelira Therapeutics' Total Receivables compare to MTNB and SXTP?
Zelira Therapeutics' Total Receivables of A$0.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current Total Receivables is A$0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current Total Receivables of A$0.03 Mil. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current Total Receivables is A$0.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current Total Receivables is A$0.03 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelira Therapeutics Business Description

Other Exchanges ZLDAF:USA
Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.